-
Sodium Orthovanadate in Phosphorylation Assays
2026-09-01
Sodium Orthovanadate (Na3VO4) is a reversible phosphate-mimetic inhibitor for preserving phosphorylation signals. This guide connects inhibitor choice, adipocyte insulin-signaling biology, assay controls, and practical workflow design.
-
MLN8237: A Translational Aurora A Strategy
2026-09-01
Aurora A biology is emerging as a tractable vulnerability in tumors shaped by RB1 loss, MYCN dysregulation, and aggressive disease features. This thought-leadership article explains how MLN8237 (Alisertib) can help translational researchers connect kinase selectivity with biomarker strategy, mechanistic validation, and more decision-ready cancer models.
-
Z-IETD-FMK in Morphotype-Specific Apoptosis
2026-08-31
Z-IETD-FMK provides a mechanistic way to test caspase-8 involvement in pathogen-induced apoptosis. This article connects its pharmacology with Candida krusei morphotype-specific signaling and practical assay design.
-
Salvianolic acid B in Pulmonary Fibrosis
2026-08-31
Salvianolic acid B, also called Dan Shen Suan B, supports a mechanism-led workflow for studying LH2-associated collagen remodeling rather than measuring total collagen alone. This guide translates the reference findings into practical cell-based assay design, formulation controls, orthogonal readouts, and troubleshooting steps.
-
ER-Fusogenic Liposomes Strengthen Antitumor Vaccines
2026-08-30
The reference study develops phosphatidylinositol-based immunomodulatory nanoliposomes that combine intrinsic dendritic-cell activation with endoplasmic-reticulum membrane fusion. In mouse models, OVA-loaded PI-INLs enhanced CD8 T-cell responses and tumor control compared with MF59-adjuvanted OVA, supporting a self-adjuvanting strategy for cellular cancer vaccines.
-
gamma-Glu-Cys (γ-Glu-Cys): Protocol Guide
2026-08-29
gamma-Glu-Cys (γ-Glu-Cys) provides a defined intermediate for glutathione synthetase enzyme assay development, glutathione metabolism research, and selected plant stress adaptation studies. It should be used as a research reagent with freshly prepared solutions and appropriate controls, not as a clinical, diagnostic, or automatically validated biological treatment.
-
Shaped ABC Coil-Bottlebrush Terpolymer Assembly
2026-08-28
This study examines how the sequence and side-chain length of shaped ABC coil–bottlebrush terpolymers control melt self-assembly. Across a highly uniform series, the architecture favored hexagonal and lamellar morphologies while systematically suppressing double-gyroid formation, revealing that bottlebrush shape can override phase behavior expected from composition alone.
-
Dabigatran Evidence for Thromboembolic Prevention
2026-08-28
This 2015 review synthesizes the pharmacology, clinical trial evidence, and practical safety considerations surrounding dabigatran, the first widely introduced direct oral thrombin inhibitor. Its key contribution is linking predictable anticoagulant exposure with evidence across atrial fibrillation, postoperative venous thromboembolism prevention, and treatment of established venous thromboembolism.
-
Potassium Iodide: Designing Evidence-Bound Assays
2026-08-27
Potassium Iodide is a defined iodide source for thyroid hormone synthesis and radioactive iodine thyroid blocking research. This guide distinguishes established KI workflows from exploratory links to immunotherapy, helping researchers design better controls and interpret evidence responsibly.
-
Cytarabine (AraC): From DNA Stress to Translation
2026-08-27
A thought-leadership guide to using Cytarabine as a mechanistically interpretable DNA-synthesis stressor, with emphasis on deoxycytidine kinase activation, p53-mediated apoptosis, resistance biology, assay design, and the carefully bounded connection to RIPK3-dependent inflammatory cell death.
-
Recombinant Human FGF-19 in Renal Signaling
2026-08-26
Recombinant Human FGF-19 offers a controlled way to investigate FGFR4-dependent endocrine signaling alongside renal inflammatory models. This article translates WIP1–p38 MAPK–pyroptosis findings into a receptor-aware assay strategy while clearly separating established evidence from testable FGF-19 hypotheses.
-
ERCC1 Deficiency, p53, and Platinum Response in Lung Cancer
2026-08-26
Heyza and colleagues used CRISPR-Cas9-engineered lung cancer models to show that ERCC1 deficiency does not predict cisplatin response independently of p53 status. Their findings identify p53-dependent apoptosis, altered interstrand crosslink repair kinetics, and DNA-PKcs/BRCA1 activity as important variables when interpreting ERCC1 as a platinum-response biomarker.
-
Phytol Workflows for RXR Signaling and Assays
2026-08-25
Build more informative Phytol experiments by combining solvent-aware dosing, RXR transcriptional readouts, and orthogonal checks for metabolism and GABAergic effects. A polymer self-assembly study adds a useful design lesson: systematically map composition, architecture, and time rather than assuming one condition predicts the whole response.
-
Spatial Proteomics of Therapeutic-Releasing Brain Probes
2026-08-25
This 2026 Journal of Materials Chemistry B study develops a titania nanotube array coating that combines antimicrobial activity with localized therapeutic release on intracortical microelectrodes. Spatial proteomics identified how neuronal integrity, immune activation, and cytokine-associated responses vary around the probe, providing design guidance for side-specific coatings and future chronic neural interfaces.
-
PDHA1 Succinylation, α-KGA, and Immune Escape
2026-08-24
A 2025 Nature Communications study identifies PDHA1 lysine 83 succinylation as a metabolic control point in cholangiocarcinoma. The modification increases α-ketoglutaric acid accumulation, activates macrophage OXGR1–MAPK signaling, suppresses MHC-II antigen presentation, and may contribute to chemotherapy resistance.